African national genome projects: what they could change for patients and health systems

Genetic information has become part of how doctors identify disease, interpret DNA tests and, sometimes, choose treatments. Most of the evidence behind it, however, comes from people living outside Africa, even though the continent holds the widest range of human genetic variation. In a piece published on 11 October 2026 by The Conversation and republished by Eastleigh Voice, Mohamed Zahir Alimohamed, a molecular geneticist at Muhimbili University in Tanzania, looks at how African countries are trying to correct this imbalance through national genome projects.

A gap with consequences

A genome is a person’s full set of DNA. Alimohamed notes that African participants make up about 0.15 per cent of those enrolled in genome-wide association studies, the large analyses that look for statistical links between genetic variants and illness.

That imbalance can distort interpretation. In one case he cites, researchers found that some variants once blamed for a hereditary heart disorder in people of African descent were harmless. The error was easier to spot once data from African-ancestry groups grew more plentiful.

A test result is only useful if clinicians know what a change means. With richer data from African populations, the author argues, some inherited conditions could be diagnosed more clearly, families could receive better information about diseases that run in their lineage, and researchers could better explain why patients react differently to the same drug.

How the first national programmes differ

Alimohamed wrote the underlying paper with co-authors from Kenya, South Africa, Senegal, Tunisia and Egypt. Tunisia, Egypt and Senegal already run national initiatives, while the paper places Tanzania, Kenya and South Africa at an earlier phase and does not assess how they are being carried out. A national genome project reads many genomes to see how people in one country differ genetically, and how some of those differences connect to health.

• Tunisia intends to recruit both healthy people and patients, a design that could help tell harmless variation from changes that matter for an illness.
• Egypt wants to cover far more people and to examine both frequent and rare conditions. The open question is whether that size can be converted into usable knowledge and clinical capacity.
• Senegal wants its sample to include 31 ethnolinguistic groups spread over all 14 regions, so that a dataset called national does not leave out part of the population.

The authors argue that no single model fits every country. They add that the same questions apply wherever a project stands, as the author’s account on Eastleigh Voice explains: who is represented, how data are governed, whether local skills grow and whether findings eventually reach clinics. They also point to H3Africa, the Human Heredity and Health in Africa initiative, which already helped set up laboratories, train researchers and build partnerships. National programmes, they say, should draw on that experience while following each country’s own health priorities and resources.

What would make the effort worthwhile

The goal is not a test for every citizen. It is to produce knowledge that is still missing and to develop the people and systems able to use it. A family facing an inherited disease might learn more quickly whether a variant is behind it, and locally gathered evidence would let researchers study diseases that weigh on their own populations. None of this follows automatically: thousands of sequenced genomes accomplish little where nobody can analyse the data or turn discoveries into care.

The practical list is long: laboratories, computing, trained scientists and clinicians able to interpret genomic results, plus firm rules covering consent, privacy, data storage and permitted users. The authors suggest that governments settle the health questions a project should answer, bring communities into its design and fix consent and data-access arrangements before collecting any sample. Budgets, they say, should pay for training, secure data systems and interpreters of the results, not just sequencing.

Contributors hand over very personal information, so they should be told why it is collected, how it is protected, who can use it and what their communities may gain. International partnerships remain valuable, but countries should keep real control over the data drawn from their own populations.

Can countries afford it?

Many African health systems already carry a heavy load: infectious disease, too few health workers and a rising burden of cancer and cardiovascular illness. The paper does not frame genomics as a competitor to these needs. It suggests starting at a size a country can sustain, concentrating on local health problems and expanding as capacity grows, with regional cooperation as a way to share sequencing, data analysis and training. Funding length matters too: projects that rest only on short research grants may yield data but struggle to keep staff and equipment once the money stops.

How to judge success

Counting the people whose DNA gets read is the simplest way to describe such a project, yet the authors say it should not be the main yardstick. What matters to the public is what changes because it exists: better reading of genetic tests, clearer answers for families with inherited disease, stronger evidence for treating African patients, and local skills and services that outlast the sequencing phase.

These programmes will not reshape healthcare overnight, and their value rests on turning data into knowledge, sturdier health systems and services people can use. African genomic data matter to global science, and the countries and communities supplying them should benefit as well.

The full argument is available in the original article by Mohamed Zahir Alimohamed, which Eastleigh Voice republished from The Conversation.

Featured image. Source: Pixabay. Credit: kennethr. License: Pixabay Content License.